A Study of LY4175408 in Participants With Advanced Cancer
Public ClinicalTrials.gov record NCT07046923. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
Study identification
- NCT ID
- NCT07046923
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 240 participants
Conditions and interventions
Conditions
Interventions
- LY4175408 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2025
- Primary completion
- Jun 30, 2030
- Completion
- Jun 30, 2030
- Last update posted
- Apr 16, 2026
2025 – 2030
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Center | Stanford | California | 94305 | Recruiting |
| Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute | Orlando | Florida | 32827 | Recruiting |
| Florida Cancer Specialists - Sarasota | Sarasota | Florida | 34236 | Recruiting |
| The University of Chicago Medical Center (UCMC) | Chicago | Illinois | 60637 | Recruiting |
| Community Health Network | Indianapolis | Indiana | 46250 | Not yet recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Washington University | St Louis | Missouri | 63110 | Recruiting |
| John Theurer Cancer Center At Hackensack UMC | Hackensack | New Jersey | 07601 | Recruiting |
| Columbia University | New York | New York | 10032 | Recruiting |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| The Ohio State University (OSU) Wexner Medical Center | Columbus | Ohio | 43210 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
| NEXT Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07046923, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07046923 live on ClinicalTrials.gov.